

**RESEARCH****INDIA STRATEGY | FY27 BUDGET REVIEW**

Continues to lay building blocks for the long term. Unlikely to be a short-term market catalyst

**BOB ECONOMICS RESEARCH | BUDGET FY27**

Analysis of Union Budget 2026-27

**SUN PHARMA | TARGET: Rs 2,109 | +32% | BUY**

All round beat; growth momentum to continue

**SUMMARY****INDIA STRATEGY: FY27 BUDGET REVIEW**

- Budget 2026 largely met muted expectations around it as much had been accomplished in and outside previous budgets
- Believe by itself it will not move earnings materially for FY27 but lays ground for better growth from a medium to long term perspective
- In 2026, paper supply will absorb domestic flows while valuation, AI driven faster earnings growth in other EMs may keep FPIs disinterested

[Click here](#) for the full report.

**INDIA ECONOMICS: BUDGET FY27**

To arrive at budget ratios, government makes some critical assumptions. Government expects nominal GDP to rise by 10% in FY27, recovering from 8% growth in FY26. Overall tax revenue-GDP is estimated to remain broadly stable at 11.2% in FY27BE. Direct tax-GDP ratio is expected to increase to 6.9% from 6.8% last year. Indirect tax-GDP ratio will remain steady at 4.3% as per FY27BE. Capex is expected to rise by 11.5% in FY27BE to Rs 12.2 lakh crore following 4.2% growth registered in FY26RE (Rs 11 lakh crore). Overall size of the budget, as % of GDP, has been brought further down to 13.6% in FY27BE from 13.9% in FY26RE. Fiscal deficit ratio in FY27BE is targeted at 4.3%, down from 4.4% in FY26RE.

[Click here](#) for the full report.





## SUN PHARMA

- Domestic sales growth driven by volume growth of 6.3% vs IPM volume growth of 1.2% due to leadership position across 14 categories
- Global innovative sales ex-of milestone income contributed 21% of total sales, with milestone contribution increasing to 24% of total sales
- On a strong innovative portfolio, we continue to ascribe a PE of 34x and roll forward to Dec'27 EPS to arrive at TP of Rs 2,109. Maintain BUY

[Click here](#) for the full report.



## FY27 BUDGET REVIEW

02 February 2026

### Continues to lay building blocks for the long term. Unlikely to be a short-term market catalyst

- Budget 2026 largely met muted expectations around it as much had been accomplished in and outside previous budgets
- Believe by itself it will not move earnings materially for FY27 but lays ground for better growth from a medium to long term perspective
- In 2026, paper supply will absorb domestic flows while valuation, AI driven faster earnings growth in other EMs may keep FPIs disinterested

Girish Pai  
 Research Analyst  
 Research Team  
 Research Analyst  
 research@bobcaps.in

**With much accomplished in and outside earlier budgets market went into the current one with low expectations:** Income Tax giveaway in FY26 budget, GST rate rationalization from September 2025, Monetary easing (repo rate cut by 125bps over the last 12 months) were among those actions. After supporting capex since Feb 2021, FY26 saw a pivot towards supporting consumption. FY27 budget seems balanced.

**Key asks going into the budget FY27:** (1) Keep growth going at a reasonable clip through both balanced capex and consumption growth (2) support areas of the economy which have been impacted by US tariffs and also those that could drive exports through the various FTAs being signed by India (with EU, UK, etc). (3) thrust on generating employment (4) get recent depreciation of INR under control (5) keep cost of capital low by keeping 10-year G sec yields under control. They hit one year peak of ~6.7% despite repo rate cuts of 125 bps in the last 12 months.

**See market likely to trade in a large range in 2026:** With Nifty earnings growth expected to pick up in FY27 (~17% based on Bbg) after a lackluster FY26 (~1%), and a lower valuation premium vis-à-vis EM peers there is a widespread expectation that Indian equities will do well in 2026 relative to 2025 (Nifty up ~10.5% in local currency terms). AI/Digital driven faster and supposedly structural earnings growth for some key corporates in Taiwan, South Korea and China is likely to keep FPIs from looking at India in a meaningful way. Domestically, strong retail flows into equities have been absorbed by large supply of paper through IPOs, FPOs and QIPs. Consensus view is that 2026 is going to be as strong on this front if not stronger than 2025. We therefore think that while easing valuation premium and the structural earnings compounding story will keep the market from falling too much, the above two points will keep the market reigned in. The change in taxation on Buybacks may help support stock prices.

**Sectors that are likely to outperform:** Prefer domestic sectors at reasonable valuations. BFSI is the only sector that fits that description. In many other domestic sectors, we believe valuations are not reasonable as they seem to be more than adequately pricing in the earnings turnaround from various fiscal and monetary policy actions and hence the need to go stock by stock.





## BUDGET FY27

01 February 2026

### Analysis of Union Budget 2026-27

To arrive at budget ratios, government makes some critical assumptions. Government expects nominal GDP to rise by 10% in FY27, recovering from 8% growth in FY26. Overall tax revenue-GDP is estimated to remain broadly stable at 11.2% in FY27BE. Direct tax-GDP ratio is expected to increase to 6.9% from 6.8% last year. Indirect tax-GDP ratio will remain steady at 4.3% as per FY27BE. Capex is expected to rise by 11.5% in FY27BE to Rs 12.2 lakh crore following 4.2% growth registered in FY26RE (Rs 11 lakh crore). Overall size of the budget, as % of GDP, has been brought further down to 13.6% in FY27BE from 13.9% in FY26RE. Fiscal deficit ratio in FY27BE is targeted at 4.3%, down from 4.4% in FY26RE.

Economics Research Department  
Economist

#### Glide path

- Government has committed that “starting FY27 till FY31, the Government would endeavour to keep fiscal deficit in each year such that the Central Government debt is on declining path”.
- In the speech, FM reiterated that “Central Government would target reaching a debt-to-GDP ratio of  $50 \pm 1\%$  by FY31”.
- Government aims to lower its debt-GDP ratio from 56.1% in FY26RE to 55.6% in FY27BE.
- The FY26RE print also includes the liabilities on account of investment in Special Securities of the States, under the NSSF, which are expected to be 0.7% of GDP.

#### Tax collections

- Gross tax collections are estimated to register significant incremental improvement in FY27BE compared with last year (Rs 3.3 lakh cr).
- This will be driven by double-digit increase in both corporate and income tax receipts.
- This also implies that corporate profitability is expected to maintain momentum.
- Indirect tax receipts are expected to come down marginally, noting the impact of rationalization of GST rates.
- This decline will be compensated by expected increase in both customs and excise collections.





**BUY****TP: Rs 2,109 | ▲ 32%****SUN PHARMA**

| Pharmaceuticals

| 01 February 2026

## All round beat; growth momentum to continue

- Domestic sales growth driven by volume growth of 6.3% vs IPM volume growth of 1.2% due to leadership position across 14 categories
- Global innovative sales ex-of milestone income contributed 21% of total sales, with milestone contribution increasing to 24% of total sales
- On a strong innovative portfolio, we continue to ascribe a PE of 34x and roll forward to Dec'27 EPS to arrive at TP of Rs 2,109. Maintain BUY

Foram Parekh  
 Research Analyst  
[research@bobcaps.in](mailto:research@bobcaps.in)

**Earnings upbeat** – Sales grew by 13% YoY to Rs 155 bn, driven by year-on-year growth of 16% in the domestic region, 28% in emerging markets (EMs), 21% in the ROW region and 6% in the US region; which was offset by 5% decline in the API sales. During the quarter, there was a milestone income of USD55mn from the ROW market (Rs4.9bn), excluding which the sales rose by 10% YoY. Healthy product mix led to an all-time high Gross Margin of 81% and EBITDA margin of 30.9%. However, excluding for the milestone income, Gross Margin was at 80.4% and EBITDA Margin at 28.6%. During the quarter, there was an exceptional item of Rs 4.8bn recorded, where Rs 3.7bn was allotted to the International Labour Code and the balance to GSMDL settlement. Adjusting against milestone and exceptional costs, PAT reported 6% decline YoY to Rs 32.1bn.

**Global innovative sales on new launches** – During the quarter, SUNP's global innovative sales went up by 14% YoY to USD 423 mn. Sun also witnessed a growth of 22% YoY to USD 55 mn in its milestone income from the RoW region, while ex-of milestone, global innovative sales rose by 13% to USD 368 mn. The growth was driven by new launches like Unloxcyt and Ilumya in the US and domestic regions, respectively. Global innovative sales gaining traction from both US and non-US regions, thereby clocking sales of USD 1bn in 9MFY26, ex-of milestone. As both the newly launched drugs are witnessing healthy early feedback, we expect FY26E global innovative sales to report USD ~1.4bn.

**Domestic region continues to grow in double digits** – Domestic sales were 5% above our estimates to Rs 50bn. The growth is driven by volume growth of 6.3% vs IPM volume growth of 1.2% and 12 new launches during the quarter. Volume growth was driven by sustaining leadership position in Rx across 14 Dr's categories. This has led to increase in Sun's market share to 8.4% as on Dec'25 MAT vs the earlier market share of 8.1%. Going forward, SUNP is expected to launch Semaglutide injectables on the 1st day of LoE and expects enhanced access to the product. Given its unwavering leadership in the IPM, we expect Sun to continue surpassing IPM growth and report 12% CAGR from FY26-28E to Rs 243.5bn in FY28E.

## Key changes

Target	Rating
▲	◀ ▶

Ticker/Price	SUNP IN/Rs 1,595
Market cap	US\$ 41.6bn
Free float	45%
3M ADV	US\$ 40.9mn
52wk high/low	Rs 1,851/Rs 1,548
Promoter/FPI/DII	54%/16%/20%


Source: NSE | Price as of 30 Jan 2026

## Key financials

Y/E 31 Mar	FY25A	FY26E	FY27E
Total revenue (Rs mn)	525,785	580,124	639,439
EBITDA (Rs mn)	153,869	168,339	193,436
Adj. net profit (Rs mn)	118,260	118,199	137,519
Adj. EPS (Rs)	49.3	49.3	57.3
Consensus EPS (Rs)	49.3	48.3	55.3
Adj. ROAE (%)	16.9	15.2	15.6
Adj. P/E (x)	32.4	32.4	27.8
EV/EBITDA (x)	26.5	24.6	22.0
Adj. EPS growth (%)	16.2	(0.1)	16.3

Source: Company, Bloomberg, BOBCAPS Research

## Stock performance



Source: NSE





**NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.**

## Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited**

Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051**

SEBI Research Analyst Registration No: **INH000000040 valid till 03 February 2025**

Brand Name: **BOBCAPS**

Trade Name: **www.barodaetrade.com**

CIN: **U65999MH1996GOI098009**



Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

### Recommendation scale: Recommendations and Absolute returns (%) over 12 months

**BUY** – Expected return >+15%

**HOLD** – Expected return from -6% to +15%

**SELL** – Expected return <-6%

**Note:** Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

### Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

### Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

### General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.



BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

#### Other disclosures

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

#### Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "**Losses**") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

#### Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "**MAYBANK**"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

#### No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

#### Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.